Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors
Authors
Keywords
Neuroendocrine tumor, Carcinoid tumor, Carcinoid syndrome, Somatostatin, Octreotide
Journal
MEDICAL ONCOLOGY
Volume 35, Issue 9, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-04
DOI
10.1007/s12032-018-1189-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
- (2017) Daniel M Halperin et al. LANCET ONCOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors
- (2016) Chan Shen et al. ONCOLOGIST
- Carcinoid and Neuroendocrine Tumors: Building on Success
- (2015) Pamela L. Kunz JOURNAL OF CLINICAL ONCOLOGY
- Neuroendocrine Tumors, Version 1.2015
- (2015) Matthew H. Kulke et al. Journal of the National Comprehensive Cancer Network
- Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review
- (2015) Michael S Broder WORLD JOURNAL OF GASTROENTEROLOGY
- Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
- (2015) Edward Wolin et al. Drug Design Development and Therapy
- Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
- (2015) Khalid Al-Efraij et al. Cancer Medicine
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study
- (2014) J. R. Strosberg et al. ONCOLOGIST
- Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin
- (2013) H. Jann et al. NEUROENDOCRINOLOGY
- Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
- (2011) William H. Ludlam et al. ADVANCES IN THERAPY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period
- (2011) Lowell Anthony et al. PANCREAS
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started